Nexell Therapeutics Inc.

Joan A Kobori

Sam L Helgerson

Robert J Deans

Fahad A Al-Abdaly

Janet Tseng-Law

Roy Guillermo

The invention provides a nonenzymic method for the release of cells which have been selected from a heterogeneous cell suspension by antibody-mediated binding to beads or other solid support. The method entails forming within the cell suspension a complex comprising the solid support linked to a primary monoclonal antibody, which in turn is bound to a cell surface antigen on the target cells. The complex is separated from the cell suspension, and then contacted with a specific peptide which binds to the primary antibody, displacing the antibody from the cell surface antigen, thereby releasing the target cell from the complex. The invention also provides methods for positive/negative cell selection wherein target cells having a first antigen are selected from a heterogeneous cell suspension containing undesired cells having a second antigen.

Positive and positive/negative cell selection mediated by peptide release

The invention provides a non-enzymatic method for the release of cells which have been positively selected from a heterogeneous cell suspension by antibody-mediated binding to beads or other solid support. The method entails forming within the cell suspension a complex comprising the solid support linked to a primary antibody, which in turn is specifically bound to a cell surface antigen on the target cells. The complex is separated from the cell suspension, and then contacted with a specific peptide which binds to the primary antibody, displacing the antibody from the cell surface antigen, thereby releasing the target cell from the complex. The invention also provides methods for positive/negative cell selection wherein target cells having a first antigen are selected from a heterogeneous cell suspension containing undesired cells having a second antigen. The invention also provides methods for identifying a specific peptide useful for the release of a target cell from the binding of a specific primary antibody. The methods of the invention are particularly useful for the positive selection of CD34+ hematopoietic stem cells and the concomitant purging of undesired tumor cells or lymphocytes from the positively selected cell population. The purified CD34+ cell composition is then useful for reinfusion to a cancer patient after high-dose therapy in order to reconstitute the patient's immune system.

Growing community of inventors

Pasadena, CA, United States of America

Joan A Kobori